VOLUME 23 NUMBER 6 JUNE 2016 nature structural & molecular biology a r t i c l e s BRD4 plays an important role in cellular functions such as transcription, replication, epigenetic regulation and DNA repair 1 . It was originally identified as a chromatin-binding scaffold that recruits transcription factors and chromatin modifiers 2, 3 . It also functions as a mitotic 'bookmark' of genes transcriptionally reactivated in early G1 (refs. 4, 5), including MYC, FOS and AURKB 4, (6) (7) (8) . Studies have revealed that BRD4 binds to promoters and nucleates super-enhancers 9 , thus suggesting that BRD4 has an active role in gene regulation. Indeed, BRD4 not only passively scaffolds transcription factors such as PTEFb and NF-κB but also actively regulates transcription elongation [10] [11] [12] .
a r t i c l e s BRD4 plays an important role in cellular functions such as transcription, replication, epigenetic regulation and DNA repair 1 . It was originally identified as a chromatin-binding scaffold that recruits transcription factors and chromatin modifiers 2, 3 . It also functions as a mitotic 'bookmark' of genes transcriptionally reactivated in early G1 (refs. 4,5) , including MYC, FOS and AURKB 4, [6] [7] [8] . Studies have revealed that BRD4 binds to promoters and nucleates super-enhancers 9 , thus suggesting that BRD4 has an active role in gene regulation. Indeed, BRD4 not only passively scaffolds transcription factors such as PTEFb and NF-κB but also actively regulates transcription elongation [10] [11] [12] .
Transcriptional activation depends on the acetylation of nucleosomal histones and chromatin decompaction around targeted genes, thus making them accessible to transcription factors 13, 14 . Acetylation neutralizes the positive charges of lysine residues on nucleosomal histones, thereby weakening their interactions with DNA and adjacent nucleosomes 15 . Specific histone acetylation marks also serve as docking sites for chromatin adapters and modifiers described as 'readers' 16, 17 . BRD4 is one such reader, and it is preferentially recruited to histones acetylated at H3 K14 or H4 K5 or K12 (refs. 10,18) . Although the role of acetylation of the lysines in the N-terminal tail, which are positioned on the nucleosome surface, has been extensively analyzed, less is known about the effect of acetylation of lysines located within histone C-terminal globular domains. Modifications of lysines within the globular domain, which lie on the lateral surface of the histone octamer in direct contact with DNA, can destabilize the nucleosome and affect overall chromatin architecture 19 . Acetylation of histone H3 K122, positioned on the dyad axis of the nucleosome where the DNA-histone bond is strongest, causes histone eviction and nucleosome instability 20 . Acetylated (ac) H3 K122 on chromatinized templates is associated with increased transcription rates in vitro 20 . In vivo, H3K122ac is concentrated at active enhancers and promoters and correlates with transcription; conversely, the absence of H3K122ac is associated with transcriptional silencing. Currently, p300 and CBP are the only HATs known to acetylate H3 K122 (ref. 20) . Blocking BRD4's interaction with histones with the I-BET inhibitor decreases histone acetylation levels at promoter regions 21 . Additionally, depletion of BRD4 leads to selective hypoacetylation of histones H3 and H4 (ref. 22) .
All known HATs dissociate from chromatin during mitosis 23 , thus raising the question of how mitotic chromosomes are reacetylated for chromatin decompaction and transcriptional reactivation. Intriguingly, BRD4 overexpression results in chromatin decompaction and accelerated transcriptional reactivation after mitosis 24 . However, BRD4 does not interact with or recruit any of the known HATs, including p300, GCN5, PCAF, CBP and Tip60 (refs. 7,25) .
The above observations led us to investigate whether BRD4 has HAT activity and plays an active role in mediating chromatin decompaction. We report that BRD4 has intrinsic HAT activity that acetylates the tail lysines of nucleosomal histones H3 and H4. Importantly, BRD4 also acetylates the H3 K122 residue in the globular core of the histone octamer, thus resulting in histone eviction, nucleosome clearance and chromatin decompaction, with a correlated increase in nuclear volume and transcription. Genome wide, H3K122ac colocalizes with BRD4. BRD4-mediated nucleosome clearance is dependent on its HAT activity and targets genomic loci where BRD4 is known to bind. Furthermore, BRD4 depletion, and the consequent decrease in histone acetylation, correlates with aberrant thymic development in vivo. These studies identify an active role for BRD4 in regulating chromatin structure, suggesting a model in which BRD4's roles in chromatin decompaction and transcription are integrated.
RESULTS

BRD4 has intrinsic acetyltransferase activity
Because many bromodomain proteins (for example, CBP and TAF1) are known HATs, we speculated that BRD4 might also have HAT activity. Indeed, recombinant mouse BRD4 efficiently acetylated histones H3 and H4 ( Fig. 1a and Supplementary Fig. 1a) ; we also detected BRD4 autoacetylation (Fig. 1a and Supplementary Fig. 1b) . BRD4 HAT activity remained consistent regardless of the source or the method of purification (Fig. 1b) . Importantly, the BRD4 HAT activity is intrinsic: in an in-gel HAT assay with mouse and human BRD4, acetylated H4 peptides were associated with only BRD4 (Fig. 1c) .
We next examined BRD4's substrate specificity. BRD4 acetylated all four core histones-although it preferentially acetylated H3 and H4-as well as histone H1 ( Fig. 1d and Supplementary Fig. 1c,d ). In contrast, BRD4 did not acetylate any of its nonhistone partners that we examined (Supplementary Table 1 ). Therefore, BRD4 is an acetyltransferase whose primary targets are histones. BRD4 also efficiently acetylated mononucleosomes assembled in vitro on 5S rDNA, exhibiting a preference for nucleosomal H3 (Fig. 1e) . BRD4 acetylation of nucleosomal histones contrasts with that of p300, which preferentially acetylates H4 (Fig. 1e) . Furthermore, meta-analysis of chromatin immunoprecipitation (ChIP)-seq data demonstrated that inhibition of BRD4 binding to chromatin by either of two smallmolecule BRD4 inhibitors, iBET or JQ1, resulted in decreased histone acetylation (Supplementary Fig. 2a ). BRD4 overexpression in HeLa cells resulted in a global increase in the acetylation levels of H3 and H4 (average of 2.2 and 2.3 times in magnitude, respectively) (Fig. 1f) .
Indeed, BRD4 overexpression resulted in increased H3 acetylation in multiple cell lines of both human and mouse origin, thus demonstrating that BRD4 acetylates histones in a wide range of cell types (Supplementary Fig. 2b ). Thus, BRD4 is an acetyltransferase that acetylates nucleosomal histones both in vitro and in vivo.
BRD4 HAT activity maps to predicted acetyl CoA-binding sites
We next mapped the BRD4 domains responsible for its HAT activity. Two regions of mouse BRD4 matched the highly conserved motif A, a known recognition and binding sequence for acetyl CoA, (R/Q)XXGX(G/A) 26 : one site (amino acids (aa) 175-180) lies in the N terminus adjacent to bromodomain 1, and the other (aa 1097-1102) is in the C terminus. Point mutations at either site abrogated BRD4 HAT activity (Fig. 2a) . Thus, the HAT activity of BRD4 maps to sites homologous to acetyl CoA-binding sites. BRD4 has no significant sequence similarity to catalytic domains of known HATs. However, deletion of a 40-aa segment (aa 1157-1197; ∆40AA) in the C terminus abolished BRD4 HAT activity. In contrast, deletion of a 60-aa (aa 1340-1400; 60AA) spanning the interaction sites of proteins such as PTEFb and HPV E2 did not affect BRD4 HAT activity. Combinations of these mutations abrogated HAT activity (Fig. 2a) , whereas BRD4 mutants lacking either or both bromodomains retained HAT activity (Fig. 2b) . Therefore, BRD4 HAT activity depends on a 40-aa region in the C terminus, which probably contains the catalytic domain, and on two sites homologous to acetyl CoA-binding sites; however, this activity does not depend on the bromodomains. Introduction of homologous mutations into human BRD4 (∆NT CoA Bs and ∆40AA) similarly abrogated its HAT activity (described below).
BRD4 HAT mutants retained their ability to bind histones (Fig. 2c) . BRD4 bound unacetylated histones, albeit with lower affinity than that toward acetylated histones 18 ; this binding was significantly enhanced in the presence of acetyl CoA (Supplementary Fig. 2c) a r t i c l e s npg a r t i c l e s JQ1, an acetyl-lysine mimic that binds BRD4 bromodomains and inhibits binding to histones 27 , significantly decreased acetylation (Supplementary Fig. 3a) . At high concentrations, JQ1 also blocked the HAT activity of the BRD4 mutant lacking both bromodomains, thus suggesting that JQ1 directly inhibits BRD4 catalytic activity (Supplementary Fig. 3a ).
BRD4 HAT differs from known histone acetyltransferases
We next determined which lysine residues in the N-terminal tails of H3 and H4 are acetylated by BRD4, because differential acetylation can lead to distinct functional consequences 16 . BRD4 efficiently acetylated H3 K4, K9, K18 and K27, and all of these acetylated residues are associated with open chromatin and active transcription (Fig. 3a) . Like p300, BRD4 acetylated H4 at K5, K8, K12 and K16. However, whereas p300 acetylated H4 K5, K8 and K12 residues with comparable efficiency, BRD4 showed preferential acetylation of, from highest to lowest preference, K8, K5, K12 and K16 (Fig. 3a) . a r t i c l e s with specific antibodies (Fig. 3a) . This finding is notable because all other known H3 acetyltransferases acetylate H3 K14 (refs. 15,16,28) . This pattern of H3 acetylation distinguishes BRD4 from other HATs. Although BRD4 is capable of acetylating most H3 tail lysines and all H4 tail lysines, it does so with different kinetics, thus demonstrating its selectivity in vitro ( Supplementary Fig. 3b ,c). Although H3 K14 was not detectably acetylated by BRD4, H3K14ac stimulates BRD4 binding to H3 (ref. 18) . Indeed, BRD4 acetylation of H3 peptides was more efficient for peptides that were preacetylated at K14, compared with either unacetylated or H3K9ac peptide controls ( Supplementary Fig. 3d ). Thus, although H3 K14 is not a substrate for acetylation by BRD4, H3K14ac is a docking site for BRD4, positioning it for subsequent acetylation of other lysine residues.
The patterns of BRD4 acetylation of H3 and H4 lysine residues observed in vitro were also present in vivo. Expression of exogenous BRD4, compared with controls, resulted in increased acetylation of H3 K4, K9, K18 and K27 (Fig. 3b) . We also observed increased acetylation of H4 K5, K8, K12 and K16 (Fig. 3c) . Importantly, BRD4 overexpression did not affect H3K14ac levels (Fig. 3b) . Because all previously known HATs acetylate H3 K14, the absence of increased H3K14ac after BRD4 overexpression indicated that the increased acetylation at other histone lysine residues is a direct effect of BRD4 HAT activity. These patterns of acetylation define a BRD4 HAT 'fingerprint' . Furthermore, BRD4 overexpression led to a significant increase in nuclear H3K9ac, thereby indicating that BRD4 acetylates chromatin-bound H3 (Fig. 3d) . Thus, BRD4 acetylates histones in vitro and in vivo.
BRD4 HAT activity has a distinct inhibition profile relative to those of other known HATs. The broad-spectrum HAT inhibitors anacardic acid and garcinol inhibited BRD4 acetylation of both H3 and H4, but curcumin did not (Fig. 3e) , thereby distinguishing BRD4 from other HATs. BRD4 HAT activity increased with increasing pH, showing the highest activity between pH 8.0 and pH 9.0 ( Supplementary  Fig. 3e ). This result is consistent with previous findings that histone acetylation correlates with intracellular pH 29 .
BRD4 acetylates H3 K122 in the globular domain of histone H3
The increase in nuclear volume accompanying in vivo overexpression of BRD4 (Fig. 3d) suggested that BRD4 mediates chromatin decompaction and nucleosome eviction. Nucleosome eviction depends on acetylation of H3 K122 in the globular domain in the histone octamer 20 (Fig. 4a) . Strikingly, BRD4 acetylated H3 K122 in vitro (Fig. 4b) . Mass spectrometric analysis confirmed that BRD4 acetylates H3 K122 (Supplementary Fig. 4a ). In addition, overexpression of BRD4 markedly increased H3K122ac levels in vivo ( Fig. 4c and  Supplementary Fig. 4b ). Increased H3 K122 acetylation depended on BRD4 HAT activity: none of the HAT-defective mutants increased H3K122ac levels, whereas both the ∆60AA mutant, which retained HAT activity, and wild-type (WT) BRD4 did increase H3K122ac levels (Supplementary Fig. 4b) . Levels of H3K14ac, a substrate not targeted by BRD4, remained unchanged.
In contrast, depletion of BRD4 in HeLa cells by short interfering RNA (siRNA) led to a 51% decrease in H3K122ac levels, and decreases in the more labile H3K18ac and H4K5ac were even greater (90% and
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Anti-histone H3 npg a r t i c l e s 73%, respectively) (Fig. 4d) . The decrease in H3K122ac was particularly striking because it is a very stable modification whose turnover is normally undetectable in cells 30 , thus suggesting that BRD4 maintains H3K122ac levels. We speculate that the residual H3K122ac observed in BRD4-depleted cells is maintained by p300/CBP. Notably, H3K14ac and H3K56ac levels remained unchanged. BRD4 acetylation of H3 K122 was independent of p300 and CBP, the only HATs previously known to acetylate H3 K122, as shown in two different ways. First, siRNA depletion of p300 and CBP decreased but did not eliminate total H3K122ac levels. The residual H3K122ac probably reflects endogenous BRD4 HAT activity. Strikingly, exogenously expressed BRD4 restored H3K122ac levels to control levels in cells depleted of p300 and CBP; however, the BRD4 HAT mutant did not restore H3K122ac levels (Fig. 4e) . Second, we treated cells expressing exogenous WT or mutant BRD4 with curcumin, a potent inhibitor of p300 and CBP but not BRD4 HAT activity ( Supplementary Fig. 4c and Fig. 4f) . Curcumin treatment decreased H3K122ac levels in the control and BRD4 HAT mutant-transfected cells, a result reflecting the loss of p300 and CBP activity. However, exogenous WT BRD4 largely restored H3K122ac levels (>70%) (Fig. 4f) . In both sets of experiments, H3K56ac, which is a product of exclusively p300 and CBP, was completely eliminated, thus demonstrating the complete loss of p300 and CBP activity. Therefore, we conclude that BRD4 acetylates H3 K122 independently of p300 and CBP.
To further document the direct role of BRD4 in acetylating histone H3, we treated cells transfected with exogenous WT BRD4 or vector control with increasing amounts of the BRD4-bromodomain inhibitor JQ1 (Fig. 4g) . JQ1 caused a dramatic decrease in H3K122ac and H3K18ac levels both in control cells expressing only endogenous BRD4 and in cells expressing exogenous BRD4 (Fig. 4g and  Supplementary Fig. 4d) . Notably, although cells depleted of p300 and CBP had decreased H3K122ac, JQ1 inhibition of BRD4 binding to chromatin decreased H3K122ac levels even further ( Supplementary  Fig. 5a ). Levels of H3K14ac, whose formation is not mediated by BRD4, were unaffected in JQ1-treated cells. Thus, BRD4 contributes to acetylation of H3 K122 and H3 K18 through its binding to chromatin. Supporting these results, in vivo H3K122ac levels correlated with BRD4 genome wide, as evidenced by meta-analysis of ChIP-seq data in which >93% of BRD4-bound sites colocalized with H3K122ac peaks (Fig. 4h) . Furthermore, H3K122ac levels peaked at sites of maximal BRD4 binding (Fig. 4i) ; neither the intensity nor the pattern of this colocalization correlated with those of other transcription factors or p300 and CBP (Supplementary Fig. 5b) . Together, these results demonstrate that BRD4 acetylates H3 K122 in vivo. BRD4 is the only HAT other than p300 and CBP shown to acetylate this critical residue.
BRD4 mediates histone eviction and nucleosome clearance
The findings that BRD4 acetylates H3 K122 as well as the tails of both H3 and H4, and that its overexpression leads to increased nuclear volume, led us to speculate that BRD4 HAT activity might contribute to nucleosomal disassembly. Indeed, BRD4 mediated the dissociation of mononucleosomes and the release of free DNA in the presence of acetyl CoA, and this was accompanied by the acetylation of nucleosomal H3 at K9 and K122 (Fig. 5a) . The addition of JQ1 to the reaction prevented mononucleosomal disruption. TAF1, another double-bromodomain HAT that acetylates histone-tail lysines, did not acetylate H3 K122 or release DNA from the mononucleosomes (Fig. 5a) . BRD4 mutants lacking HAT activity were unable to mediate mononucleosome disruption or acetylate mononucleosomal H3 K9 and K122 (Fig. 5b) . The ∆60AA BRD4 mutant retained HAT activity and also retained the ability to disrupt the mononucleosomes (Fig. 5b) . Together, these results demonstrate that BRD4 acetylation of mononucleosomal H3 K122 mediates nucleosome disassembly.
We next tested whether BRD4 similarly evicts nucleosomes from native chromatin by assessing BRD4-mediated changes in micrococcal nuclease (MNase) sensitivity, which increases with decreased nucleosome occupancy. Chromatin incubated in vitro with increasing amounts of BRD4 was increasingly sensitive to MNase digestion; increased MNase digestion of chromatin depended on the presence of acetyl CoA and was inhibited by JQ1 (Fig. 5c) . Thus, BRD4 disrupts nucleosomes from native chromatin in vitro, creating stretches of open DNA. BRD4 also mediated nucleosome clearance from chromatin in vivo. Exogenous expression of WT but not HAT-mutant BRD4 in U2OS cells resulted in a marked increase in MNase digestion of chromatin relative to that of the control (Fig. 5d) . Accordingly, we observed higher levels of H3K122ac and H3K9ac in these cells relative to the cells expressing the BRD4 HAT mutant or controls (Fig. 5d) . We conclude that BRD4 HAT activity mediates clearance of nucleosomes from chromatin in vivo.
BRD4 HAT modulates nucleosomal occupancy genome wide
We next sought to determine whether BRD4 regulated nucleosome occupancy genome wide, by using MNase-seq analysis. Strikingly, expression of WT but not mutant BRD4 significantly decreased nucleosome occupancy downstream of transcription start sites (TSSs) (Fig. 6a and Supplementary Fig. 5c ). Accordingly, BRD4 substantially increased RNA expression levels genome wide as a function of decreased nucleosome occupancy (Fig. 6b) . Thus, BRD4 HAT activity contributes to the decreased nucleosome occupancy associated with transcriptionally active genes.
BRD4 binds to and plays a critical role in regulating expression of proto-oncogenic M-G1 cell-cycle regulators, for example, MYC, FOS and AURKB 2, 7, 8 . Indeed, BRD4 but not the HAT mutant decreased nucleosome occupancy around the TSSs of MYC, FOS and AURKB (Fig. 6c) . The sites of BRD4 HAT-mediated nucleosome clearance correspond to the sites where BRD4 has been shown to bind 7 . Thus, nucleosome clearance by BRD4 can be highly localized. In contrast, nucleosome occupancy around AURKA 8 , which is BRD4 independent, was only marginally affected by BRD4 (Fig. 6c) . Concomitantly with BRD4-effected decreases in nucleosome occupancy, RNA levels of MYC, FOS and AURKB were significantly increased (Fig. 6d) . We conclude that BRD4 mediates the nucleosome clearance that precedes transcriptional activation at its target genes.
We next determined whether BRD4 binding around the TSSs of MYC, AURKB and AURKA would result in nucleosomal H3 K122 acetylation in vivo (Fig. 6e) . Levels of H3K122ac but not H3K14ac increased in parallel with WT BRD4 occupancy at the MYC and AURKB loci but not at the AURKA loci. Strikingly, JQ1 treatment reversed the increase in H3K122ac seen with WT BRD4 expression, but there was no effect on H3K14ac levels or at the AURKA locus. In contrast, the BRD4 HAT mutant, which bound as efficiently as WT BRD4 to the target loci, did not cause an increase in H3K122ac (Fig. 6e) . Consistently with the observed increases in RNA levels after BRD4 overexpression, RNA polymerase II (Pol II) occupancy increased around the MYC and AURKB but not AURKA loci (Supplementary Fig. 6 ). We conclude that BRD4 directly acetylates nucleosomal histones, thus leading to the clearance of nucleosomes from its target loci and providing access to the transcription machinery.
The effects of BRD4 on H3 K122 acetylation and chromatin decompaction could also be visualized directly. In U2OS cells, introduction of WT hBRD4, but not the hBRD4 mutant lacking HAT activity a r t i c l e s (Mt BRD4), resulted in a dramatic increase in H3 K122 acetylation, as determined by immunofluorescence and increased nuclear volume, an indicator of chromatin decompaction (Fig. 7a,b) . Consistently with the inability of BRD4 to acetylate H3 K14, the H3K14ac levels were unchanged.
BRD4 deletion decreases H3K122ac levels in the thymus
We next examined the effect of BRD4 deletion in vivo on H3K122ac levels and mouse thymic development. Immature thymocytes, which express neither CD4 nor CD8 cell-surface molecules (double negative, DN), transition into thymocytes expressing both CD4 and CD8 (double positive, DP) and finally into cells expressing either CD4 or CD8. The transition from DN to DP is accompanied by extensive proliferation and differentiation, in which we predicted BRD4 might play a role.
Conditional deletion of BRD4 in the thymus (BRD4 KO) was achieved by expressing Cre from the Lck promoter, which is active only in early DN thymocytes. Thymocytes from the BRD4-KO mice had no detectable BRD4 protein (Fig. 7c) . As compared with the thymi from either control or BRD4 heterozygotes, Brd4 −/− thymi had a dramatically different profile of CD4 and CD8 expression, as assessed by flow cytometry (Fig. 7c) . BRD4 deletion resulted in an increase in the proportion of immature DN thymocytes (from 3% to 15%) and a corresponding decrease in the more mature DP cells (from 85% to 60%). Thus, BRD4 is required for normal development of thymocytes beyond the DN stage.
H3K122ac levels were markedly, albeit modestly (33%), decreased in the thymi of BRD4-deficient mice. This modest decrease is consistent with both the long half-life of H3K122ac and its continued acetylation by p300 and CBP 30 . Accordingly, levels of the more labile H3K18ac and H4K5ac were dramatically decreased (85% and 61%, respectively). Levels of H3K14ac, which has a short half-life, remained unchanged, consistently with the decreases in H2K122ac, H3K18ac and H4K5ac, thus reflecting the loss of BRD4 (Fig. 7c) .
To further document the effect of BRD4 deletion on acetylation of H3K122 in vivo, we generated mouse embryonic fibroblasts (MEFs) from mice heterozygous for the floxed Brd4 allele (Brd4 fl/− ). We examined the ability of exogenous BRD4 to restore H3K122ac after Cre deletion of endogenous BRD4. Deletion of BRD4 by Cre resulted in cell death; cell viability was rescued by exogenous BRD4. Exogenous WT BRD4 completely restored H3K122ac levels, whereas the HAT mutant was unable to do so (49% of parental levels) (Fig. 7d) ; the levels of exogenous BRD4 proteins were comparable to the original endogenous levels (Supplementary Fig. 7) . The levels of H3K122ac observed in MEFs rescued with the HAT mutant were comparable to those observed when BRD4 was silenced (Fig. 4d) , thus suggesting that in both cases the residual H3K122ac was derived from p300 and CBP. Therefore, BRD4 HAT activity contributes to in vivo H3K122ac levels. DISCUSSION BRD4, originally identified in association with mitotic chromosomes and implicated in cell-cycle control 18 , has key roles as a mitotic bookmark and as a passive scaffold for transcription factors (reviewed in ref. 31 ). However, BRD4 is also an active participant in transcription through its intrinsic kinase activity, which phosphorylates S2 of the Pol II Cterminal domain (CTD) 11, 32 . The present study demonstrates that BRD4 has an extended role: an intrinsic HAT activity distinct from (4) (5) (6) (7) (1) (2) (3) (1) (2) (3) (1) (2) with H3K122ac genome wide, and its acetylation of H3 leads to nucleosomal disassembly and nuclear expansion, consistently with chromatin decompaction. BRD4 preferentially decreases nucleosome occupancy around the genes that it is known to bind and regulate, a r t i c l e s such as MYC, FOS and AURKB. Furthermore, conditional deletion of BRD4 in the thymus results in decreased H3K122ac levels and perturbations in thymic development. Thus, BRD4 is an active remodeler of chromatin as well as an active transcriptional regulator. Nucleosomal disassembly and chromatin decompaction mediated by BRD4 HAT activity occur preferentially at its target loci and at sites where BRD4 binds and where H3K122ac is enriched 7, 20, 33 . Although we found that BRD4 decompacted chromatin at its known targets, such as MYC, FOS and AURKB genes, it did not markedly affect nucleosome occupancy around the AURKA gene, which it does not regulate 8 . A previously reported >95% correlation between BRD4 occupancy and DNase I-hypersensitivity sites genome wide 34 is consistent with our conclusion that BRD4 clears nucleosomes at its target gene loci.
The finding that BRD4 HAT activity decompacts chromatin resolves an apparent paradox in the literature. It has been reported that a truncated isoform of BRD4 insulates chromatin from decompaction 3 . We suggest that this isoform, which lacks the HAT catalytic domain, is a competitive inhibitor of full-length BRD4, which has HAT activity. Accordingly, overexpression of the truncated BRD4 isoform, containing only the N-terminal bromodomains, results in the aggregation of chromatin into highly compact regions 35 . However, in a previous study, depletion of BRD4 has been found to result in increased MNase sensitivity, thus leading the authors to conclude that BRD4 is necessary for higher-order chromatin structure 35 . We speculate that this Figure 8 Model for the role of BRD4 histone acetyltransferase activity. Cartoon shows BRD4 being recruited to acetylated histone lysines (for example, H3 K14) in nucleosomes associated with gene loci targeted for expression, such as the MYC and FOS G1 genes. Once recruited to chromatin, BRD4 acetylates histones, thereby weakening histone-DNA interactions through the acetylation of tail lysines and globular H3 K122 and causing localized nucleosome disassembly and clearance followed by increased transcription. effect was not due to BRD4-mediated compaction but instead to chromothripsis induced either by premature chromosome condensation or by an inability to decondense 36 . That is, BRD4 overexpression and depletion both lead to altered chromatin structures, but these effects have different underlying causes. BRD4 also acts as a critical regulator of transcription, both by recruiting PTEFb to promoters and by phosphorylating S2 of the Pol II CTD through its intrinsic kinase activity, a modification necessary for transcriptional elongation 11 . Our discovery that BRD4 has intrinsic HAT activity that regulates chromatin remodeling leads to the conclusion that BRD4 actively links chromatin remodeling and transcription, as described in the following model (Fig. 8) . We speculate that BRD4 contributes to remodeling of chromatin first through its binding to H3K14ac at promoters or enhancers and second by acetylation of both tail lysines and H3 K122 in the globular domain of adjacent histone octamers, thus leading to nucleosome eviction around the TSSs of target genes. The decreased nucleosomal occupancy allows access to the transcriptional machinery and recruitment of transcription factors, including PTEFb, thereby resulting in transcription activation. After transcription initiation, BRD4 triggers pause release through phosphorylation of the Pol II CTD 32, 37 (Fig. 8) . Future experiments will focus on defining the molecular mechanisms that regulate BRD4 HAT activity.
In conclusion, we demonstrate that BRD4 actively regulates chromatin structure through its HAT activity and speculate that BRD4 links chromatin structure-through its acetylation and eviction of nucleosomal histones-with transcription, through its phosphorylation of the Pol II CTD. Additionally, the discovery of BRD4 HAT activity should enable the development of new inhibitors that specifically target its HAT activity for the treatment of cancers and autoimmune diseases.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Cell lines and culture. HeLa, U2OS, DLD1, MCF-7, NIH3T3 and mouse kidney cells (kind gift of T. Reid, NCI, NIH) were grown in DMEM with 10% FBS at 37 °C and 7.5% CO2. Cell lines were tested for mycoplasma contamination and authenticated by spectral karyotyping or arrayCGH. Drosophila Sf9 cells were grown at 27 °C in TNM-FH insect medium (BD Biosciences Pharmingen).
Plasmid constructs. Mouse Flag-His-BRD4 WT and B1, B2 and B1B2 mutants were as described previously 11 . His 6 -BRD4-Flag 40AA and 60AA mutants were generated as dropout mutants; NT CoA Bs, CT CoA Bs and NT-CT CoA Bs BRD4 were generated as point mutants by using primers with site-specific mutations. 40AA-NT CoA Bs, 40AA-CT CoA Bs and 40AA-NT-CT CoA Bs BRD4 mutants were generated through a combination of dropout and sitespecific mutations with the BRD4 WT construct used as a template. WT BRD4 and mutants generated in the pACHLTc insect vector were moved into the mammalian pCDNA3.1 vector by excising the BRD4 sequences with BamH1 and SmaI and subcloning them into pCDNA3.1 by using BamH1 and EcoRV. The GST-tagged human BRD4 in pGEX-6P-1 was from the Addgene repository (Addgene plasmid 14447). Human Flag-tagged BRD4 WT in the pCMV2 mammalian vector was a gift from E. Verdin (Gladstone Institute of Virology, University of California, San Francisco). The hBRD4 40AA-NT CoA Bs double mutant was generated by using the WT hBRD4 in the pCMV2 vector as a PCR template. The Flag-dTAF1 construct used to make recombinant TAF1 in Sf9 cells was as described previously 38 .
Transient transfections. Transient transfections into mammalian cells were performed with Lipofectamine (Invitrogen). Cells were treated with 5 mM sodium butyrate during transfection to inhibit HDAC activity and were harvested 18 h after transfection. WCE were analyzed by immunoblotting with specific antibodies, as indicated in the figures. BRD4 knockdown was carried out by Lipofectamine-mediated transfection of 80 nM siRNA (ON-TARGETplus Smartpool human BRD4 or siGENOME nontargeting siRNA pool, Dharmacon) into HeLa cells. WCE were prepared 24, 48 and 72 h after siRNA transfection and used for immunoblotting. CBP and p300 knockdowns were generated by transfecting 10 nM, 25 nM or 35 nM of ON-TARGETplus Smartpool human CBP, p300 or siGENOME nontargeting siRNA pool (Dharmacon), respectively, into U2OS cells. WCE were prepared 72 h after transfection and used for immunoblotting. In experiments in which CBP and p300 knockdowns were performed in combination with JQ1 treatment, 500 nM of JQ1 or an equal volume of DMSO was added 18 h before harvesting of siRNA-transfected cells.
Reagents. Antibodies used for immunoprecipitation or immunoblotting were anti-BRD4 (H-250; sc-48772); anti-H4ac (sc-34263; Santa Cruz Biotech); antiH3K4ac (07-539; Millipore); anti-H3ac (06-599; Upstate); anti-H3K9ac, antiH3K14ac, anti-H3K18ac, anti-H3K27ac, anti-H3K56ac and anti-H3 (from 9927 kit, Cell Signaling); anti-H4 (F-9: Santa Cruz Biotech); anti-H4K5ac, anti-H4K8ac, anti-H4K12ac and anti-H4K16ac (from 17-211 kit, Millipore); anti-β-tubulin (ab6046; Abcam); CBP (A-22: sc-369, Santa Cruz Biotech); p300 (3G230/NM-11, ab-14984, Abcam); and anti-H3K122ac (ab33309; Abcam). Validation of the specificity of the anti-H3K122ac (lots 436839 and GR14667-1) and other antibodies used in the study is provided on the manufacturers' websites. HAT inhibitors anacardic acid, curcumin and garcinol (Biovision) and C646 (Sigma) were dissolved in dimethyl sulfoxide (DMSO) to make concentrated stock solutions. Stock solutions of all HAT inhibitors were stored at −80 °C. The (+)-JQ1 inhibitor (BPS Bioscience) was similarly dissolved in DMSO and stored.
Recombinant proteins and peptides. Flag-tagged BRD4 and Flag-tagged dTAF1 were purified from Sf9 cells as previously described 11 . His 6 -tagged WT BRD4 and derived mutant proteins were purified with an Ni-NTA spin-column kit (Qiagen) according to the manufacturer's instructions. Control extracts (mock) from uninfected Sf9 cells were prepared similarly. The purity of the His 6 -tagged BRD4 used in the study was assessed by mass spectrometric analysis (RPLC-MS/ MS; NCI Laboratory of Proteomics), thus confirming the absence of any known HAT in the sample. GST-tagged hBRD4 was expressed and purified from E. coli cells (BL21 Rosetta-gami strain, Novagen) by inducing expression with 0.8 mM IPTG overnight at 18 °C and performing repeated pulldowns and concentration with GST-Sepharose beads (Amersham Pharmacia). Purified proteins were concentrated with Microcon size-exclusion columns (Millipore), recovered in HKEG buffer (20 mM HEPES, pH 7.9, 100 mM KCl, 0.2 mM EDTA and 20% (v/v) glycerol) and stored frozen at −80 °C. Highly purified (>99%) human histone H1.0, H1.4, H2A, H2B, H3, H4, H3.1, H3.2 and H3.3 substrates were from New England BioLabs (NEB) as recombinant proteins expressed in E. coli; their purity was confirmed by the company through mass spectrometry analysis (ESI-TOF MS) and peptide sequencing. Synthetic histone H4(1-21) and histone H3(1-21) peptides were from SignalChem. Synthetic histone H3 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , histone H3(1-19), H3K14ac and H3K9ac peptides were from AnaSpec. Recombinant p300, expressed and purified from Sf9, with purity confirmed at >95%, was from ProteinOne.
Immunoprecipitation and immunoblots. WCE were prepared from transfected cells with tissue extraction reagent (Invitrogen), per the manufacturer's instructions. All immunoblot analyses were performed with secondary antibodies (IRDye 800CW goat anti-rabbit IgG (H+L) and IRDye 680RD goat anti-mouse IgG (H+L); 926-32211 and 926-68070, Li-Cor Biosciences) from Li-Cor and the Odyssey infrared scanner. Specific antibodies were as indicated in the figures. BRD4 and BRD4 mutant binding to histones was detected by first subjecting equimolar amounts (0.6 µg) of His 6 -tagged BRD4 proteins and 1 µg of histone H3 to a HAT assay in the presence or absence of 0.5 mM acetyl CoA for 30 min at 30 °C. Subsequently, the reactions were incubated for 2 h at 4 °C with equal amounts of Ni-NTA agarose beads to pull down BRD4 proteins with associated histones. Bead-bound proteins were washed twice with 50 mM Tris, pH 8.0, 100 mM NaCl, and 0.1% NP-40 and immunoblotted with both anti-BRD4 and anti-histone H3 antibodies to detect bead-bound BRD4 and associated histone H3.
Solution HAT assays. HAT assays were performed as previously described, with minor changes 38 . Purified BRD4 (500 ng), TAF1 (625 ng) or p300 (750 ng) was incubated with 1 µg histone substrate (NEB), 70 nCi of The reactions were stopped with SDS sample buffer; samples were run on 15% SDS-PAGE gels, fixed overnight, dried and exposed to a tritium PhosphorImager screen. Histone acetylation was analyzed with a Storm PhosphorImager with ImageQuant software. HAT assays analyzed by immunoblots were performed as described above, but with 0.6 mM unlabeled acetyl CoA (Sigma), and immunoblotted with the appropriate antibody.
Filter binding HAT assay. Filter binding HAT assay was performed as previously described 39 and analyzed by capturing the acetylated products on Whatman filter paper. After stringent washes to remove residual free acetyl CoA, acetylation levels were quantified with a Microbeta Trilux scintillation counter.
In-gel HAT assay. The in-gel HAT assay was performed as previously described 40 , with modifications as follows. Three sets of 3 µg purified rBRD4, hBRD4 and mock Sf9 extract were run on a 6% SDS-PAGE gel containing 1 mg/ml H4 peptide. The gel was cut into three strips, each with one set of proteins each. One set was denatured with 8 M urea for 1 h and renatured for 16 h, after which which the gel strip was soaked in HAT buffer containing 2.5 mM acetyl CoA and 1 mM sodium butyrate for 1.5 h at 30 °C. The gel was washed three times in 5% TCA to remove unbound acetyl CoA, further washed three times with Tris-glycine-SDS buffer and immunoblotted with an anti-H4ac antibody. This immunoblot was aligned with the other two gel strips containing BRD4 and mock extract that were silver stained or immunoblotted with anti-BRD4 antibody.
In vitro nucleosome assembly. Purified 5S rDNA (208 bp) was from NEB. Unmodified recombinant human nucleosomes were assembled on the 5S rDNA with purified human histone H2A-H2B dimers and histone H3-H4 tetramers with the EpiMark Nucleosome Assembly kit (NEB), per the manufacturer's instructions.
Immunofluorescence analysis. Cells were plated on cover slips and transfected with either a vector control or BRD4, with the addition of 5 mM sodium butyrate. 18 h after transfection, cells were fixed with 4% paraformaldehyde, permeabilized npg
